Literature DB >> 22219347

Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation.

Seung H Kang1, Rima C Abdel-Massih, Robert A Brown, Ross A Dierkhising, Walter K Kremers, Raymund R Razonable.   

Abstract

Immunity against cytomegalovirus (CMV) is initiated after its recognition by Toll-like receptor 2 (TLR2). We assessed the association between a single-nucleotide polymorphism (SNP) that impairs TLR2 function and CMV disease in a cohort of 737 liver recipients. Ninety-two of 737 patients (7.1%, 10.9%, 12.3%, and 12.5% by 3, 6, 12, and 24 months, respectively) developed CMV disease. Kaplan-Meier estimation demonstrated an association between TLR2 R753Q SNP homozygosity and CMV disease (P = .044), especially tissue-invasive CMV disease (P = .001). A multivariate Cox proportional hazard model that accounted for other significant predictors demonstrated a significant association between TLR2 R753Q SNP homozygosity and tissue-invasive CMV disease (hazard ratio, 3.407; 95% confidence interval, 1.518-7.644; P = .0029). In conclusion, homozygosity for TLR2 R753Q SNP is a marker for CMV disease risk, especially for tissue-invasive disease, after liver transplantation. This observation supports the critical role of TLR2 in the pathogenesis of CMV disease in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22219347      PMCID: PMC3266129          DOI: 10.1093/infdis/jir819

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.

Authors:  Raymund R Razonable; Hester van Cruijsen; Robert A Brown; Jennie A Wilson; William S Harmsen; Russell H Wiesner; Thomas F Smith; Carlos V Paya
Journal:  J Infect Dis       Date:  2003-05-09       Impact factor: 5.226

Review 2.  Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease.

Authors:  Ross Lazarus; Donata Vercelli; Lyle J Palmer; Walt J Klimecki; Edwin K Silverman; Brent Richter; Alberto Riva; Marco Ramoni; Fernando D Martinez; Scott T Weiss; David J Kwiatkowski
Journal:  Immunol Rev       Date:  2002-12       Impact factor: 12.988

3.  Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Authors:  Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Mark D Pescovitz
Journal:  Am J Transplant       Date:  2004-04       Impact factor: 8.086

4.  Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes.

Authors:  Lutz Hamann; Axel Hamprecht; Abuzeid Gomma; Ralf R Schumann
Journal:  J Immunol Methods       Date:  2004-02-15       Impact factor: 2.303

Review 5.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

6.  Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2.

Authors:  Teresa Compton; Evelyn A Kurt-Jones; Karl W Boehme; John Belko; Eicke Latz; Douglas T Golenbock; Robert W Finberg
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

Authors:  Carlos V Paya; Jennie A Wilson; Mark J Espy; Irene G Sia; Michael J DeBernardi; Thomas F Smith; Robin Patel; Greg Jenkins; William S Harmsen; David J Vanness; Russell H Wiesner
Journal:  J Infect Dis       Date:  2002-03-19       Impact factor: 5.226

8.  A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection.

Authors:  E Lorenz; J P Mira; K L Cornish; N C Arbour; D A Schwartz
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

9.  High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR.

Authors:  Nicolas W J Schröder; Corinna Hermann; Lutz Hamann; Ulf B Göbel; Thomas Hartung; Ralf R Schumann
Journal:  J Mol Med (Berl)       Date:  2003-05-13       Impact factor: 4.599

10.  Delayed-onset primary cytomegalovirus disease after liver transplantation.

Authors:  Supha K Arthurs; Albert J Eid; Rachel A Pedersen; Ross A Dierkhising; Walter K Kremers; Robin Patel; Raymund R Razonable
Journal:  Liver Transpl       Date:  2007-12       Impact factor: 5.799

View more
  29 in total

Review 1.  Cytomegalovirus infection in liver transplant recipients: updates on clinical management.

Authors:  Jasmine Riviere Marcelin; Elena Beam; Raymund R Razonable
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

Review 3.  Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Arshad
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

4.  R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88.

Authors:  Yanbao Xiong; Chang Song; Greg A Snyder; Eric J Sundberg; Andrei E Medvedev
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

5.  Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.

Authors:  Elena Beam; Raymund R Razonable
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

6.  Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia.

Authors:  U Schnetzke; B Spies-Weisshart; O Yomade; M Fischer; T Rachow; K Schrenk; A Glaser; M von Lilienfeld-Toal; A Hochhaus; S Scholl
Journal:  Genes Immun       Date:  2014-11-27       Impact factor: 2.676

Review 7.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

Review 8.  Genetic variants of innate immune receptors and infections after liver transplantation.

Authors:  Gemma Sanclemente; Asuncion Moreno; Miquel Navasa; Francisco Lozano; Carlos Cervera
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Management of cytomegalovirus infection and disease in liver transplant recipients.

Authors:  Jackrapong Bruminhent; Raymund R Razonable
Journal:  World J Hepatol       Date:  2014-06-27

Review 10.  New Developments in the Management of Cytomegalovirus Infection After Transplantation.

Authors:  Atibordee Meesing; Raymund R Razonable
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.